** Biotech firm Bio-Techne's TECH.O shares rise 4.8% to $76 premarket
** TECH beat Q2 earnings estimates, driven by growth in its protein sciences unit that develops biological compounds for research, diagnostics, and cell and gene therapy
** The protein sciences unit's sales rose 7% to $211.6 mln
** Company reports Q2 adj profit of 42 cents per share, above analysts' est of 39 cents - LSEG
** Posts Q2 sales of $297 mln, above analysts' est of $285.7 mln - LSEG
** TECH fell ~6% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.